Changes for page Customer segments in Health and Wellbeing Living Labs
Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.8
edited by Sarantis Dimitriadis
on 2022/06/07 08:45
on 2022/06/07 08:45
Change comment:
There is no comment for this version
To version 5.1
edited by XWikiGuest
on 2022/01/10 15:43
on 2022/01/10 15:43
Change comment:
Added annotation on "Researcher expertise"
Summary
-
Page properties (2 modified, 0 added, 0 removed)
Details
- Page properties
-
- Author
-
... ... @@ -1,1 +1,1 @@ 1 -XWiki. Sarantis1 +XWiki.XWikiGuest - Content
-
... ... @@ -1,320 +318,3 @@ 1 -(% class="western" lang="en-GB" style="text-align:justify" %) 2 -(% lang="en-US" %)**End user:** A person who ultimately uses or is intended to ultimately use the product, service or process. In living lab project, end user is defined as a primary study participant who voluntarily participates research after giving informed consent to be the subject of the research. 3 - 4 -(% class="western" lang="en-GB" style="text-align:justify" %) 5 -(% lang="en-US" %)**Living lab research infrastructure end user:** A person or organization who(%%) (% lang="en-US" %)purchases or uses living lab research infrastructure services to conduct a specific contract based research and development activity (often focusing on specifically defined end user group). Living lab research infrastructure end user can also be study participant (a.k.a. end user), if living project is focusing on developing living lab services and infrastructure. 6 - 7 -(% class="western" lang="en-GB" style="text-align:justify" %) 8 -(% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following: 9 - 10 -* ((( 11 -(% lang="en-US" %)**Non-professional end users:** 12 - 13 -* (% lang="en-US" %)**Consumers: **Those who buy goods or services for their own use. 14 - 15 -* (% lang="en-US" %)**Public health and social service clients: **Those who use public services. 16 -))) 17 - 18 -* ((( 19 -(% lang="en-US" %)**Professional end users** 20 - 21 -* (% lang="en-US" %)**Health professionals and managers:** A person providing health care treatment and advice based on formal training and experience. Also known as healthcare professional or healthcare worker. 22 - 23 -* (% lang="en-US" %)**Social care workers and managers:** Those providing the practical support to help people cope with the day-to-day business of living based on formal training and experience. 24 - 25 -* (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level. 26 -))) 27 - 28 -(% class="western" lang="en-GB" %) 29 -(% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows: 30 - 31 -* ((( 32 -(% lang="en-US" %)**Private sector organizations: **(business developers and researchers) 33 - 34 -* (% lang="en-US" %)Tangible equipment and device manufactures 35 - 36 -* (% lang="en-US" %)Health and social service providers 37 - 38 -* (% lang="en-US" %)e-health, IT system and digital technology providers 39 - 40 -* (% lang="en-US" %)Wellbeing and wellness service providers 41 - 42 -* (% lang="en-US" %)Pharmaceutical companies 43 -))) 44 - 45 -* ((( 46 -(% lang="en-GB" %) 47 -(% lang="en-US" %)**Public sector organizations:** 48 - 49 -* (% lang="en-US" %)**Local level: **Municipals, cities and other local level public organizations providing e.g. health and social services such as primary health care. 50 - 51 -* (% lang="en-US" %)**Regional level: **e.g.** **Regional** **hospitals providing secondary and tertiary care,** **councils, parliaments, and governments as well as other administrative organizations operating at regional level. 52 - 53 -* (% lang="en-US" %)**National level: **Government agencies, departments or temporary pointed working groups responsible for the specific functions such as health and social services. 54 - 55 -* (% lang="en-US" %)**International level: **European commission departments and agencies as well as other organizations operating at international and transnational level. 56 - 57 -* (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process. 58 -))) 59 - 60 -* ((( 61 -(% lang="en-GB" %) 62 -(% lang="en-US" %)**Education and research organizations:** 63 - 64 -* (% lang="en-US" %)**Higher education institutes:** Universities and Universities of Applied Sciences 65 - 66 -* (% lang="en-US" %)**Other educational institutes** covering early childhood, primary, secondary and tertiary education 67 - 68 -* (% lang="en-US" %)**Public research institutions/organizations** such as technical research centers and government laboratories. 69 - 70 -* (% lang="en-US" %)**Private research organizations** such as technology and innovation centers 71 -))) 72 - 73 -* ((( 74 -(% lang="en-GB" %) 75 -(% lang="en-US" %)**Civil society organizations:** 76 - 77 -* (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level. 78 -))) 79 - 80 -* ((( 81 -(% lang="en-GB" %) 82 -(% lang="en-US" %)**Networks and clusters:** 83 - 84 -* (% lang="en-US" %)Company cluster organizations and company networks 85 -* (% lang="en-US" %)International, national, regional and local networks 86 -))) 87 - 88 -(% class="western" lang="en-GB" %) 89 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table . 90 - 91 -(% style="margin-left:auto; margin-right:auto" %) 92 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)((( 93 -(% class="western" lang="en-GB" style="text-align:center" %) 94 -(% lang="en-US" %)**Age or age group** 95 -))) 96 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 97 -(% lang="en-US" %)Specific age range 98 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 99 - 100 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 101 -(% class="western" %) 102 - 103 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 104 -(% class="western" %) 105 - 106 -))) 107 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 108 -(% class="western" lang="en-GB" %) 109 -(% lang="en-US" %)Elderly 110 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 111 -(% class="western" lang="en-GB" %) 112 -(% lang="en-US" %)Adults 113 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 114 -(% class="western" lang="en-GB" %) 115 -(% lang="en-US" %)Youth 116 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 117 -(% class="western" lang="en-GB" %) 118 -(% lang="en-US" %)Children 119 -))) 120 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 121 -(% class="western" %) 122 - 123 -))) 124 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)((( 125 -(% class="western" lang="en-GB" style="text-align:center" %) 126 -(% lang="en-US" %)**Health status** 127 -))) 128 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 129 -(% class="western" lang="en-GB" %) 130 -(% lang="en-US" %)Healthy 131 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 132 -(% class="western" lang="en-GB" %) 133 -(% lang="en-US" %)Patient 134 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 135 -(% class="western" lang="en-GB" %) 136 -(% lang="en-US" %)Rehabilitant 137 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 138 -(% class="western" lang="en-GB" %) 139 -(% lang="en-US" %)Recovered/Survivor 140 -))) 141 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 142 -(% class="western" %) 143 - 144 -))) 145 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)((( 146 -(% class="western" lang="en-GB" style="text-align:center" %) 147 -(% lang="en-US" %)**A specific disease, disorder or disability** 148 -))) 149 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 150 -(% class="western" lang="en-GB" %) 151 -(% lang="en-US" %)ADHD 152 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 153 -(% class="western" lang="en-GB" %) 154 -(% lang="en-US" %)Dementia 155 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 156 -(% class="western" lang="en-GB" %) 157 -(% lang="en-US" %)Parkinsons’ disease 158 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 159 -(% class="western" lang="en-GB" %) 160 -(% lang="en-US" %)Loneliness and Social Isolation 161 -))) 162 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 163 -(% class="western" lang="en-GB" %) 164 -(% lang="en-US" %)Autism 165 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 166 -(% class="western" lang="en-GB" %) 167 -(% lang="en-US" %)Down syndrome 168 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 169 -(% class="western" lang="en-GB" %) 170 -(% lang="en-US" %)Physical disability 171 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 172 -(% class="western" lang="en-GB" %) 173 -(% lang="en-US" %)Mental health 174 -))) 175 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 176 -(% class="western" lang="en-GB" %) 177 -(% lang="en-US" %)Cardiovascular disease 178 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 179 -(% class="western" lang="en-GB" %) 180 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF) 181 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 182 -(% class="western" lang="en-GB" %) 183 -(% lang="en-US" %)Sleep apnea/apnea 184 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 185 -(% class="western" lang="en-GB" %) 186 -(% lang="en-US" %)Mild cognitive impairment 187 -))) 188 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 189 -(% class="western" lang="en-GB" %) 190 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD) 191 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 192 -(% class="western" lang="en-GB" %) 193 -(% lang="en-US" %)Language disability 194 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 195 -(% class="western" lang="en-GB" %) 196 -(% lang="en-US" %)Substance abuse (drugs, alcohol) 197 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 198 -(% class="western" lang="en-GB" %) 199 -(% lang="en-US" %)Multiple sclerosis 200 -))) 201 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 202 -(% class="western" lang="en-GB" %) 203 -(% lang="en-US" %)Cognitive disorder (mild, major) 204 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 205 -(% class="western" lang="en-GB" %) 206 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation 207 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 208 -(% class="western" lang="en-GB" %) 209 -(% lang="en-US" %)Trauma patient 210 - 211 -(% class="western" lang="en-GB" %) 212 -(% lang="en-US" %)(e.g., a spinal cord injury) 213 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 214 -(% class="western" lang="en-GB" %) 215 -(% lang="en-US" %)Neurodegenerative diseases 216 -))) 217 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 218 -(% class="western" %) 219 - 220 -))) 221 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)((( 222 -(% class="western" lang="en-GB" style="text-align:center" %) 223 -(% lang="en-US" %)**Clients of a specific service** 224 -))) 225 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 226 -(% class="western" lang="en-GB" %) 227 -(% lang="en-US" %)Child welfare 228 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 229 -(% class="western" lang="en-GB" %) 230 -(% lang="en-US" %)Nursing home 231 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 232 -(% class="western" lang="en-GB" %) 233 -(% lang="en-US" %)Employment service 234 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 235 -(% class="western" %) 236 - 237 -))) 238 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 239 -(% class="western" lang="en-GB" %) 240 -(% lang="en-US" %)Early childhood education 241 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 242 -(% class="western" lang="en-GB" %) 243 -(% lang="en-US" %)Home care 244 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 245 -(% class="western" lang="en-GB" %) 246 - 247 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 248 -(% class="western" lang="en-GB" %) 249 - 250 -))) 251 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 252 -(% class="western" %) 253 - 254 -))) 255 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)((( 256 -(% class="western" lang="en-GB" style="text-align:center" %) 257 -(% lang="en-US" %)**Vulnerable groups** 258 -))) 259 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 260 -(% class="western" lang="en-GB" %) 261 -(% lang="en-US" %)Minors/Children 262 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 263 -(% class="western" lang="en-GB" %) 264 -(% lang="en-US" %)Single parents with minor children 265 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 266 -(% class="western" lang="en-GB" %) 267 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence 268 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 269 -(% class="western" lang="en-GB" %) 270 -(% lang="en-US" %)Substance users 271 - 272 -(% class="western" lang="en-GB" %) 273 -(% lang="en-US" %)(drugs, alcohol) 274 -))) 275 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)((( 276 -(% class="western" lang="en-GB" %) 277 -(% lang="en-US" %)Disabled people 278 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 279 -(% class="western" lang="en-GB" %) 280 -(% lang="en-US" %)Victims of trafficking in human beings 281 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 282 -(% class="western" lang="en-GB" %) 283 -(% lang="en-US" %)Ethnic minorities and immigrants 284 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 285 -(% class="western" lang="en-GB" %) 286 -(% lang="en-US" %)Isolated people 287 -))) 288 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 289 -(% class="western" lang="en-GB" %) 290 -(% lang="en-US" %)Elderly people 291 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 292 -(% class="western" lang="en-GB" %) 293 -(% lang="en-US" %)Persons with serious illnesses 294 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 295 -(% class="western" lang="en-GB" %) 296 -(% lang="en-US" %)Homeless people 297 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 298 -(% class="western" lang="en-GB" %) 299 -(% lang="en-US" %)Ex-prisoners and people with criminal background 300 -))) 301 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)((( 302 -(% class="western" lang="en-GB" %) 303 -(% lang="en-US" %)Pregnant women 304 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 305 -(% class="western" lang="en-GB" %) 306 -(% lang="en-US" %)Persons with mental disorders 307 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 308 -(% class="western" lang="en-GB" %) 309 - 310 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 311 -(% class="western" lang="en-GB" %) 312 - 313 -))) 314 - 315 -(% class="western" lang="en-GB" %) 316 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table . 317 - 318 318 |**Researcher expertise**|**Brief use case description** 319 319 |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making 320 320 |Experts in communication studies|Defining written, oral, visual and digital communication within a certain workplace. Evaluating (multi professional) healthcare team collaboration, communication and debriefing in various healthcare situations in simulated environments (especially in Simulation lab)